Artemether ameliorates DSS-induced ulcerative colitis by modulating macrophage polarization

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ulcerative colitis (UC) presents limited treatment options and low cure rates due to complex immune dysregulation.
• Artemether, an artemisinin derivative, has demonstrated therapeutic potential in other immune-related conditions.
• Understanding novel therapeutic strategies for UC is crucial.

Purpose of the Study:

• To investigate the ameliorative effects of artemether on experimental colitis in mice.
• To elucidate the underlying mechanisms by which artemether exerts its therapeutic actions in UC.

Main Methods:

• In vivo and in vitro experiments were conducted using a mouse model of colitis.
• Assessed colon inflammation, intestinal barrier integrity, and inflammatory markers.
• Investigated the role of Notch signaling and macrophage polarization.

Main Results:

• Artemether treatment significantly improved colon inflammation and intestinal barrier dysfunction in UC mice.
• Reduced levels of pro-inflammatory cytokines (IL-1β, IL-6) were observed.
• Upregulation of tight junction proteins (ZO-1, Occludin) and inhibition of intestinal leakage were noted.

Conclusions:

• Artemether demonstrates significant therapeutic potential for ulcerative colitis.
• Mechanisms involve regulating Notch signaling and suppressing pro-inflammatory M1 macrophages.
• Artemether offers a promising new therapeutic strategy for colitis treatment.